Other ·Insufficient evidence ·Reviewed May 2026
MDMA is not supported by NutriStack. Safety information only.
The bottom line
Evidence rating insufficient. 15 sources indexed (2001–2026), with 20 interaction records on file.
Dosing protocol
Listed for context; significant cardiovascular and serotonergic risk. Clinical use is in supervised research settings.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Not recommended / controlled substance.
No effective supplement dose exists. Cost is intentionally not modeled for this illegal non-medical substance. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
MDMA is a psychoactive drug, not a nutrient or food-derived supplement.
What to test, the optimal window inside the conventional range, and how long a response takes.
MDMA is detected in urine for 1 to 3 days after a single dose; metabolites include MDA which is also detected.1,2
Therapeutic MDMA-assisted psychotherapy (MAPS PTSD trials) tracks CAPS-5 and clinical outcomes, not blood. Cardiac risk: track HR, BP, ECG in patients with cardiovascular disease.
CYP2D6 pharmacogenetics is clinically relevant to MDMA metabolism and variability in exposure (PMID 23162568).
Recommendation: Known CYP2D6 poor metabolizer status should be treated as a risk amplifier for MDMA toxicity rather than a dosing guide.
Taking 5-HTP with MDMA sharply increases the risk of serotonin syndrome, a potentially life-threatening state of excess serotonergic activity with agitation, high fever, rapid heart rate, muscle rigidity, and seizures.
Recommendation: Do not combine. If symptoms such as high fever, confusion, severe muscle stiffness, or rapid heartbeat develop, seek emergency medical care immediately.
L-Tryptophan combined with MDMA raises the risk of serotonin syndrome by supplying additional serotonin precursor on top of MDMA's serotonin-releasing effect.
Recommendation: Do not combine. Watch for high fever, agitation, tremor, or muscle rigidity and seek emergency medical care if they appear.
SAMe has serotonergic and mood-elevating activity that can add to MDMA's serotonin release, increasing the risk of serotonin excess when the two are combined.
Recommendation: Do not combine. Seek medical advice, and watch for agitation, sweating, tremor, or rapid heartbeat as signs of serotonin excess.
St. John's Wort both adds to serotonergic load and induces drug-metabolizing enzymes, so combined with MDMA it can raise serotonin syndrome risk while also unpredictably altering MDMA blood levels.
Recommendation: Do not combine. Seek medical advice, and watch for signs of serotonin excess such as agitation, sweating, tremor, and rapid heartbeat.
Combining MDMA with alcohol increases dehydration, cardiovascular strain, and impaired judgment, and alcohol can mask MDMA's perceived effects while worsening next-day impairment and overheating risk.
Recommendation: Do not combine. If overheating, confusion, chest pain, or collapse occurs, seek emergency medical care immediately.
MDMA is a substituted amphetamine with strong serotonin, norepinephrine, and dopamine releasing effects. Combining it with amphetamine/dextroamphetamine can increase stimulant toxicity, including hypertension, tachycardia, hyperthermia, dehydration, agitation, panic, and arrhythmias. Risk rises sharply with dancing or strenuous activity, hot environments, redosing, or other serotonergic or stimulant substances.
Recommendation: Do not use MDMA while taking amphetamine/dextroamphetamine. Do not redose either substance to chase effects or stay awake. Seek emergency care for high fever, confusion, severe agitation, chest pain, fainting, seizure, severe headache, or a racing or irregular heartbeat.
Lisdexamfetamine produces dextroamphetamine exposure, and MDMA adds serotonergic and sympathomimetic stimulation. Co-use can increase risk of hypertension, tachycardia, hyperthermia, dehydration, agitation, panic, arrhythmias, and seizures. The longer duration of lisdexamfetamine can leave stimulant effects present well into the period when MDMA is being used or redosed.
Recommendation: Do not use MDMA while taking lisdexamfetamine. Skipping or delaying a single dose does not reliably remove risk because stimulant effects may persist for much of the day. Seek emergency care for high fever, confusion, severe agitation, chest pain, fainting, seizure, or an irregular heartbeat.
Methylphenidate and MDMA have a documented human pharmacodynamic interaction. In a controlled crossover study, the combination did not add desired psychoactive effects but did increase cardiovascular and adverse effects compared with either drug alone. This creates avoidable risk for hypertension, tachycardia, hyperthermia, anxiety, and arrhythmias, especially with redosing or hot environments.
Recommendation: Do not use MDMA while taking methylphenidate. Do not take extra MDMA if the effect feels blunted or different. Seek emergency care for high fever, confusion, severe agitation, chest pain, fainting, seizure, or a racing or irregular heartbeat.
MDMA releases and blocks reuptake of serotonin, and tramadol also inhibits serotonin reuptake while lowering the seizure threshold. Combining them can sharply increase the risk of serotonin syndrome, hyperthermia, seizures, dangerous blood pressure changes, and overdose. This is a high-risk pairing even when either substance is used only once.
Recommendation: Do not combine MDMA with tramadol. Avoid tramadol after MDMA exposure until you have medical guidance, especially if you have overheating, agitation, tremor, diarrhea, confusion, or muscle rigidity. Seek emergency care for fever, seizure, severe agitation, or altered consciousness.
MDMA causes a large serotonin release and can produce severe serotonin toxicity and hyperthermia. Sumatriptan is a serotonin receptor agonist, so using it around MDMA exposure adds avoidable serotonergic pharmacology during a high-risk state. This combination is especially dangerous with dehydration, overheating, stimulants, antidepressants, or repeated triptan dosing.
Recommendation: Do not combine MDMA with sumatriptan. If MDMA was used, avoid taking sumatriptan and seek medical advice for severe headache, chest pain, high fever, confusion, muscle rigidity, or repeated vomiting. Treat fever, agitation, clonus, or confusion after overlap as an emergency.
MDMA causes large serotonin release and can trigger severe serotonin toxicity and hyperthermia. Rizatriptan is a serotonin receptor agonist, so taking it around MDMA exposure adds avoidable serotonergic activity during an already high-risk state. Risk is higher with overheating, dehydration, stimulants, antidepressants, or repeated triptan dosing.
Recommendation: Do not combine MDMA with rizatriptan. If MDMA was used, avoid taking rizatriptan and seek medical advice for severe headache, chest pain, high fever, confusion, muscle rigidity, or repeated vomiting. Treat fever, agitation, clonus, or confusion after overlap as an emergency.
Pseudoephedrine can add to MDMA's stimulant cardiovascular effects. Controlled human studies show MDMA increases blood pressure, heart rate, and thermogenic/cardiostimulant measures, while pseudoephedrine also raises blood pressure and pulse. The combination is especially concerning during dancing, heat exposure, dehydration, panic, or underlying heart disease.
Recommendation: Do not use pseudoephedrine if you have used MDMA or may use MDMA soon. Seek urgent help for chest pain, severe headache, overheating, fainting, confusion, or a racing or irregular heartbeat. Use non-stimulant nasal congestion options instead.
Numbered references. Citations throughout the page link here.
Meta-analysis of nine trials found significant improvements in PTSD symptom severity, response, and remission rates with MDMA-assisted psychotherapy versus control.
Colcott J, Guerin AA, Carter O et al.. Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024
Hsu TW, Tsai CK, Kao YC et al.. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ (Clinical research ed.). 2024
Sarparast A, Thomas K, Malcolm B et al.. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022
Smith KW, Sicignano DJ, Hernandez AV et al.. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Journal of clinical pharmacology. 2022
Betzler F, Viohl L, Romanczuk-Seiferth N. Decision-making in chronic ecstasy users: a systematic review. The European journal of neuroscience. 2017
Straumann I, Avedisian I, Klaiber A et al.. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024
Atila C, Straumann I, Vizeli P et al.. Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials. JAMA network open. 2024
Mitchell JM, Ot'alora G M, van der Kolk B et al.. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature medicine. 2023
Phase 3 trial found MDMA-assisted therapy produced a larger reduction in PTSD severity than placebo-assisted therapy and was generally well tolerated in the trial setting.
Mithoefer MC, Wagner MT, Mithoefer AT et al.. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of psychopharmacology (Oxford, England). 2011
Figurasin R, Lee VR, Maguire NJ. 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity. 2026
Mustafa NS, Bakar NHA, Mohamad N et al.. MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity. Basic and clinical neuroscience. 2020
Papaseit E, Pérez-Mañá C, Torrens M et al.. MDMA interactions with pharmaceuticals and drugs of abuse. Expert opinion on drug metabolism & toxicology. 2020
Review documents sympathomimetic toxicity, hyperpyrexia, rhabdomyolysis, hyponatremia, and concerns about serotonergic neurotoxicity and fatalities.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack